Inflammatory Breast Carcinoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An advanced, invasive breast adenocarcinoma characterized by the presence of distinct changes in the overlying skin. These changes include diffuse erythema, edema, peau d'orange (skin of an orange) appearance, tenderness, induration, warmth, enlargement, and in some cases a palpable mass. The skin changes are the consequence of lymphatic obstruction from the underlying invasive breast adenocarcinoma. Microscopically, the dermal lymphatics show prominent infiltration by malignant cells. The invasive breast adenocarcinoma is usually of ductal, NOS type. There is not significant inflammatory cell infiltrate present, despite the name of this carcinoma. 
Inflammatory breast carcinomas most frequently harbor alterations in TP53, NOTCH2, MYC, MDM4, and MCL1 .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, MYC Amplification, and MDM4 Amplification are the most common alterations in inflammatory breast carcinoma .
There are 12 clinical trials for inflammatory breast carcinoma, of which 11 are open and 1 is completed or closed. Of the trials that contain inflammatory breast carcinoma as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 10 are phase 2 (9 open), and 1 is phase 3 (1 open).
HER2, ERBB2, and ER are the most frequent gene inclusion criteria for inflammatory breast carcinoma clinical trials .
Cyclophosphamide, paclitaxel, and doxorubicin are the most common interventions in inflammatory breast carcinoma clinical trials.
Significant Genes in Inflammatory Breast Carcinoma
ERBB2 is altered in 21.43% of inflammatory breast carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 6 clinical trials for inflammatory breast carcinoma, of which 5 are open and 1 is closed. Of the trials that contain ERBB2 status and inflammatory breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 1 is phase 3 (1 open) .
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.